Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 12Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Brenner Tumor 5Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Adenocarcinoma of Lung 3Oropharyngeal Neoplasms 2Neurotoxicity Syndromes 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinosarcoma 2Carcinoma, Transitional Cell 2Vomiting 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Resectable 1Pancreatic Adenocarcinoma 1Pancreas Adenocarcinoma 1Pain 1Ovarian Germ Cell Cancer 1

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma, Mucinous × Taxes × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡